Monitor integration of Eaze operations in California, Florida, and Colorado, and watch for shareholder approval of CEO's performance-based equity awards. The Ace Ventures partnership may create near-term cash flow challenges due to the $16 million note structure.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 7 $11.78entry
- T+1 · 7mo ago +1.88%α −0.66% · $12.00
- T+5 · 7mo ago +8.89%α +3.54% · $12.83
- T+20 · 7mo ago +6.75%α −3.04% · $12.57
- T+60 · 5mo ago −15.52%α −28.79% · $9.95
Price Chart
How similar events traded
Executive Summary
Vireo Growth Inc. completed its acquisition of Eaze Inc., issuing 90.4 million shares valued at $47 million, and simultaneously restructured its New York operations through a partnership with Ace Ventures. The company also amended its merger agreement and CEO's employment contract, including a potential $2.5 billion equity award contingent on performance milestones.
Key Financial Metrics
Key Facts
- Completed acquisition of Eaze Inc. by issuing 90,379,591 subordinate voting shares valued at $47,040,000
- Entered into partnership with Ace Venture of NY LLC for Vireo Health of New York, with Ace holding 51% ownership
- Amended CEO John Mazarakis's employment agreement with potential performance-based equity awards totaling up to 6% of fully diluted equity
- Issued $16 million promissory note from Vireo Health of New York to Vireo Health Inc. with 7% interest
- Appointed Michael Steiner to board of directors
Financial Impact
Diluted shareholders by issuing 90.4 million shares for Eaze acquisition and created $16 million intercompany note for New York operations
Risk Factors
- Integration risks from combining Eaze's operations
- Potential dilution from CEO's performance-based equity awards
- Cash flow timing mismatch in New York operations due to the $16 million note structure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-039924 |
| Document: tm2611166d1_ex10-2.htm | 0001104659-26-039924 |
| Document: tm2611166d1_ex2-2.htm | 0001104659-26-039924 |
| Document: tm2611166d1_ex99-2.htm | 0001104659-26-039924 |
| Document: tm2611166d1_ex99-1.htm | 0001104659-26-039924 |
| Document: 0001104659-26-039924-index-headers.html | 0001104659-26-039924 |
| Document: 0001104659-26-039924-index.html | 0001104659-26-039924 |
| Document: 0001104659-26-039924.txt | 0001104659-26-039924 |
Track record
21 reports on VREOF
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +18.71% at T+60 after the Jun 18, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago 3 Neutral 3/10 Entry $6.13 Now $6.29 +2.68% settles Feb 11
- Nov 13, 20263d ago 3 Neutral 2/10 Entry $6.13 Now $6.29 +2.68% settles Feb 11
- Nov 10, 20266d ago SC 13D/A Neutral 4/10 Entry $6.74 Now $6.29 −6.68% settles Feb 9
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $6.68 Now $6.29 −5.84% settles Feb 8
- Nov 3, 202614d ago EFFECT Neutral 4/10 Entry $7.45 Now $6.29 −15.57% settles Feb 1
- Oct 30, 202617d ago S-4/A Neutral 5/10 Entry $7.36 Now $6.29 −14.54% settles Jan 29
- Oct 9, 20265w ago S-4 Neutral 5/10 Entry $9.15 Now $6.29 −31.23% settles Jan 7
- Oct 8, 20265w ago 8-K Bullish 6/10 Entry $9.38 Now $6.29 −32.94% settles Jan 6
- Aug 18, 202612w ago 8-K Neutral 3/10 Entry $10.97 to $6.79 Now $6.29 −42.66% ▼ −38.10% −37.28% vs SPY
- Aug 11, 202613w ago 8-K Mixed 6/10 Entry $10.64 to $7.36 Now $6.29 −40.88% ▼ −30.83% −30.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers